President Donald Trump signed the bipartisan Laken Riley Act into law as his administration’s first piece of legislation. People who are in the United States illegally and are accused of ...
maintenance regimen of Leqembi ® (lecanemab-irmb) for early Alzheimer disease. Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble ...
Those include its new Alzheimer's drug Leqembi (lecanemab ... Qalsody (tofersen), a first-in-class therapy for a specific form of amyotrophic lateral sclerosis. "While we will be making ...
Here's how to watch The Walking Dead shows in order, including spin-offs such as Daryl Dixon season 2 ...
2025 is one of MCU's busiest years ever, which means it's about time to catch up on how to watch the Marvel movies in order if you haven ... while Phases 4-5 form part of the new Multiverse ...
Image credit: SAUL LOEB/POOL/AFP via Getty Images. President Donald Trump has signed an executive order for the US to leave the World Health Organization (WHO). As one of his first acts as the 47th ...
BioArctic AB (publ) announced that the US Food and Drug Administration (FDA) has accepted BioArctic’s partner Eisai’s Biologics License Application (BLA) for Leqembi subcutaneous ... and insoluble ...
Jan 15, 2025 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Biologics License Application (BLA) for ...
The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat individuals with mild cognitive impairment or mild dementia consistent with ...
Biogen Hits Lowest Stock Price Since 2013 as Leqembi Uptake Lags Biogen CEO Chris Viehbacher at JPM25 said that the pharma remains fully committed to the Alzheimer’s disease space and its therapeutic ...
Charles River Laboratories is predicting 2025 to be as tough as last year for CDMOs as pharma customers continue to cut costs with manufacturers. … ...
Two years ago, Biogen and partner Eisai secured accelerated FDA approval for their Alzheimer’s med Leqembi, followed by a full approval in 2023. Since then, the companies have been gradually ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback